<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05011760</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY20060171 (Aim 2)</org_study_id>
    <secondary_id>R01DA026472</secondary_id>
    <nct_id>NCT05011760</nct_id>
  </id_info>
  <brief_title>[C-11]NPA PET-amphetamine in Cocaine Use Disorders</brief_title>
  <official_title>[C-11]NPA PET-amphetamine in Cocaine Use Disorders (Aim 2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rajesh Narendran</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study uses [11C]NPA positron emission tomography (PET) and a d-amphetamine challenge to&#xD;
      image amphetamine induced dopamine release in the striatum in subjects with cocaine use&#xD;
      disorders (CUD). Amphetamine-induced dopamine release data from this study will be correlated&#xD;
      with [11C]NOP-1A VT measured at baseline in the midbrain. [11C]NOP-1A PET data will be used&#xD;
      from aim 1 (see, Study Record: Imaging CRF X NOP interactions in Cocaine Use Disorders)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cocaine use disorder (CUD) is a chronic disorder associated with numerous relapses and&#xD;
      periods of abstinence.&#xD;
&#xD;
      Studies in CUD suggest that ~ 60 to 75% of abstinent addicts relapse over twelve months.&#xD;
      Documenting specific neurochemical abnormalities that lead to relapse in individuals with CUD&#xD;
      has the potential to accelerate the development of medications to prevent relapse. Basic&#xD;
      investigations postulate an imbalance between brain stress and anti-stress/resilience systems&#xD;
      as the underlying mechanism that drives negative reinforcement, craving, and relapse in&#xD;
      addiction.. Nociceptin (N/OFQ), which binds to the nociceptive opioid peptide receptors (NOP)&#xD;
      is a critical component of the brain's anti-stress system. N/OFQ exerts its anti-stress&#xD;
      effect by counteracting the functional effects of the primary stress-promoting neuropeptide&#xD;
      corticotrophin releasing factor (CRF) in the brain. Studies have also shown that acute&#xD;
      increases in CRF and stress are countered by increased NOP receptor expression (~ 10% ) in&#xD;
      brain regions that regulate stress such as bed nucleus of the stria terminalis. PET studies&#xD;
      with the NOP radiotracer [11C]NOP-1A show increased binding to NOP in CUD compared to HC. PET&#xD;
      studies also show NOP receptors to upregulate (~ 15%) in response to an acute intravenous&#xD;
      hydrocortisone challenge (1 mg/Kg). NOP upregulation may represent an adaptive mechanism in&#xD;
      the brain to counteract stress-induced increases in cortisol and CRF. Here, we postulate a&#xD;
      failure in this adaptive mechanism as a reason that leads to relapse in CUD. CUD subjects and&#xD;
      HC will be studied with [11C]NOP-1A before and after an intravenous hydrocortisone challenge&#xD;
      (aim 1). Hydrocortisone is used as a challenge because it increases cortisol and CRF in brain&#xD;
      regions that regulate stress. We hypothesize that hydrocortisone-induced increases in&#xD;
      [11C]NOP-1A binding (DELTA VT) will be smaller in CUD relative to HC, and this will be&#xD;
      associated with less time to relapse in a 12-week follow up. Mechanistic studies have also&#xD;
      shown N/OFQ to act on ventral tegmental area/midbrain NOP receptors to inhibit the firing of&#xD;
      dopamine neurons and limit reward to cocaine. Imaging amphetamine-induced dopamine release in&#xD;
      a subset of CUD subjects who participate in aim 1 will allow us to link midbrain NOP receptor&#xD;
      expression with ventral striatum (VST) dopamine release and examine its role in reinforcement&#xD;
      (aim 2). The aims proposed in this study have the potential to clarify the role of N/OFQ and&#xD;
      NOP in stress, reward, and relapse in CUD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2028</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2028</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single group, correlational analyses</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DELTA binding potential relative to non displaceable uptake (BPND)</measure>
    <time_frame>Baseline, and 2.5 to 3 hours post-amphetamine</time_frame>
    <description>DELTA BPND is the change in BPND from the baseline PET scan to post-amphetamine PET scan that will be acquired 2.5 to 3 hours after d-amphetamine administration (0.5 mg/Kg, oral)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cocaine Use Disorder</condition>
  <arm_group>
    <arm_group_label>PET</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>[C-11]NPA PET Scan</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Baseline [C-11]NPA PET Scan</intervention_name>
    <description>Radiotracer</description>
    <arm_group_label>PET</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>d-amphetamine</intervention_name>
    <description>Oral, 0.5 mg/Kg</description>
    <arm_group_label>PET</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Post-amphetamine [C-11]NPA PET Scan</intervention_name>
    <description>Radiotracer</description>
    <arm_group_label>PET</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males or females between 18 and 55 years old&#xD;
&#xD;
          2. Fulfil DSM-5 criteria for cocaine use disorder&#xD;
&#xD;
          3. No other current DSM-5 psychiatric or addictive disorders (such as major depressive&#xD;
             disorder, bipolar disorders, psychotic disorders, etc.,)&#xD;
&#xD;
          4. No current abuse (six months) of opiates, sedative-hypnotics, amphetamines, and MDMA&#xD;
             as well as moderate to severe alcohol or cannabis use (twice a week). Nicotine use&#xD;
             will be quantified and controlled between groups using the Fagerstrom Test for&#xD;
             Nicotine Dependence (Heatherton et al., 1991);&#xD;
&#xD;
          5. Not currently on prescription medical or psychotropic medications&#xD;
&#xD;
          6. No current or past severe medical, endocrine or neurological illnesses including&#xD;
             glaucoma, seizure disorders, hypertension, hypercholesterolemia as assessed by a&#xD;
             complete medical history and physical&#xD;
&#xD;
          7. Not currently pregnant or breastfeeding&#xD;
&#xD;
          8. No history of significant radioactivity exposure in past year from another research&#xD;
             study or occupation that exceeds RDRC guidelines&#xD;
&#xD;
          9. No metallic objects in the body that are contraindicated for MRI&#xD;
&#xD;
         10. No baseline BP ≥ 140/90 and/or HR ≥ 100.&#xD;
&#xD;
         11. No first-degree relative with an MI or stroke prior to middle age&#xD;
&#xD;
         12. No first-degree relative with psychosis or mania.&#xD;
&#xD;
         13. Completed a baseline [11C]NOP-1A PET scan in Aim 1 (Study Record: Imaging CRF X NOP&#xD;
             interactions in Cocaine Use Disorders)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rajesh Narendran</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rajesh Narendran, MD</last_name>
    <phone>4126475176</phone>
    <email>narendranr@upmc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of PIttsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rajesh Narendran</last_name>
      <phone>412-647-5176</phone>
      <email>narendranr@upmc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 11, 2021</study_first_submitted>
  <study_first_submitted_qc>August 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2021</study_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Rajesh Narendran</investigator_full_name>
    <investigator_title>Professor of Radiology and Psychiatry</investigator_title>
  </responsible_party>
  <keyword>[C-11]NOP-1A, [C-11]NPA , nociceptive opioid peptide receptors, dopamine release</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amphetamine</mesh_term>
    <mesh_term>Dextroamphetamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

